1. People's Republic of China Stocks

  2. •

    Consumer Defensive

  3. •

    Packaged Foods
TECON BIOLOGY Co.LTD

TECON BIOLOGY Co.LTD

002100.SZ
TECON BIOLOGY Co.LTDCN flagShenzhen Stock Exchange
6.48
CNY
+0.07
- -
8.85BMarket Cap
TECON BIOLOGY Co.LTD
002100.SZ
(Shenzhen Stock Exchange)

Recent

price

6.48

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
3.14
3.88
4.31
4.61
4.85
4.58
4.64
4.78
5.55
6.96
11.22
14.31
12.71
14.1
12.49
12.09
8.79
Revenue per Share
0.14
0.1
0.14
0.21
0.27
0.27
0.41
0.42
0.33
0.6
1.61
-0.64
0.21
-1.01
0.44
0.15
-0.13
Basic EPS, GAAP
0.08
0.08
0.18
-0.08
0.29
0.34
0.04
0.07
-1.86
-0.97
-1.43
-0.2
-0.82
0.56
0.39
- -
-0.2
Free Cash Flow per Basic Share
0.06
0.09
0.11
0.05
0.1
0.09
0.15
0.13
0.16
0.24
0.38
0.64
0.2
0.39
0.13
0.32
0.24
Dividend per Share
0.6
0.74
0.82
1.02
1.08
1.82
2.01
2.28
2.53
2.81
4.24
3.21
2.71
1.44
1.86
1.75
1.69
Book Value per Share
1.17
1.26
1.38
1.93
2.24
2.43
2.64
2.96
3.25
4.56
6.18
6.77
6.98
5.46
5.8
5.7
5.82
Tangible Book Value per Share
755
769
772
809
873
910
957
969
951
1,074
1,069
1,098
1,337
1,350
1,375
1,404
1,361
Basic Weighted Avg Shares
2,369
2,984
3,327
3,725
4,236
4,167
4,444
4,630
5,273
7,476
11,987
15,711
16,989
19,026
17,176
16,981
11,954
Sales/Revenue/Turnover
6.64
5.59
4.73
5.33
6.75
6.82
9.68
10.06
7.86
10.16
16.93
-0.06
3.52
-3.72
5.33
3.55
1.19
Operating Margin (%)
47
59
65
91
133
164
177
182
213
317
448
705
713
803
889
832
- -
Depreciation Expense
107
77
108
170
236
246
393
407
314
644
1,720
-703
281
-1,363
605
211
-174
Net Income, GAAP
14.4
15.55
22.35
9.51
11.18
9.31
8.52
5.79
9.97
- -
1.24
- -
12.05
- -
2.36
8.47
4.14
Effective Tax Rate (%)
4.53
2.58
3.25
4.56
5.56
5.9
8.83
8.79
5.95
8.62
14.35
-4.47
1.65
-7.17
3.52
1.24
-1.46
Profit Margin (%)
450
352
212
407
563
797
884
1,812
2,311
2,393
3,325
3,641
6,188
1,874
3,353
3,455
4,186
Working Capital
178
198
98
25
19
- -
- -
936
1,576
1,586
1,542
2,353
3,436
1,588
2,379
2,189
2,830
LT Debt
1,046
1,130
1,239
1,721
2,184
2,385
2,704
3,055
3,279
5,165
6,868
7,733
9,630
7,915
8,520
8,537
8,442
Total Equity
8.47
7.77
6.18
8.51
9.67
8.56
12
10.47
6.03
- -
17.18
- -
3.31
- -
6.13
3.71
- -
Return on Invested Capital (%)
12.19
9.77
9.95
14.16
16.58
13.86
16.25
12.77
7.5
- -
18.42
- -
4.88
- -
7.74
2.55
7.12
Return on Capital (%)
26.68
15.03
17.91
23.29
26.65
18.86
21.92
19.72
13.6
23.75
45.57
-17.46
7.86
-48.94
26.9
8.4
-6.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
4,180
3,782
LT Borrowings
- -
1,876
2,552
LT Finance Leases
- -
313
278
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1,365
1,365
Market Capitalization
9,926
9,926
9,906

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
9,950
10,789
Cash, Cash Equivalents & STI
- -
2,431
3,257
Accounts Receivable, Net
- -
444
621
Inventories
- -
5,565
5,345
Total Current Liabilities
- -
6,495
6,604
Payables & Accruals
- -
- -
- -
ST Debt
- -
4,180
3,782
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.13%
5.43%
0.2%
Free Cash Flow
-284.23%
4.07%
-99.64%
Net Income, GAAP
-76.31%
-215.18%
-65.19%
Sales/Revenue/Turnover
16.72%
8.07%
-1.13%
Total Cash Common Dividend
39.81%
39.77%
155.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,777
4,216
5,094
4,089
17,176
2025
4,180
4,666
- -
3,371
16,981
2026
3,917
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.44
2025
0.11
- -
- -
- -
0.15
2026
-0.12
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
- -
- -
- -
0.13
2025
0.03
- -
- -
- -
0.32
2026
0.03
- -
- -
- -
- -
Similar Companies
Devro plc (DEVOY)
Sundrop Brands Limited (SUNDROP.BO)
Hansung Enterprise Co.,Ltd (003680.KS)
Gaodi Holdings Limited (1676.HK)
PT Cerestar Indonesia Tbk (TRGU.JK)
Tate & Lyle plc (BD15.L)
Business
TECON BIOLOGY Co.LTD engages primarily in the production and sale of veterinary biological products and animal health care, operating a vertically integrated industrial chain in modern animal husbandry. Its main products include vaccines for foot-and-mouth disease (FMD) covering strains O/A/Asia1 and swine type O; swine FMD synthetic peptide vaccines; porcine reproductive and respiratory syndrome (PRRS) live vaccines; classical swine fever (CSF) E2 inactivated and live vaccines; peste des petits ruminants (PPR) live vaccines; goat pox live vaccines; brucellosis live vaccines; black quarter inactivated vaccines; and anthrax spore live vaccines. Additionally, the company provides feed products including feed for pigs, poultry, dairy cows, ruminants, and aquatic animals, as well as veterinary pharmaceuticals, pig breeding, slaughtering, meat processing, and cold chain distribution. It also processes protein and oil products such as cotton oil and meal, and engages in agricultural products procurement, logistics, grain storage, and machinery processing. Founded in 1993 and headquartered in Urumqi, China, TECON BIOLOGY operates primarily in China with international trade activities. The company has structured its operations into five divisions: Feed, Pharmaceutical, Food Farming, Protein Oil, and Agricultural Products, thereby completing a full industry chain from fodder and breeding management to animal drugs, disease control, livestock product processing, and sales. Recent strategic developments include expanding its integrated livestock and poultry breeding ecosystem and enhancing its research and development capabilities in livestock disease vaccines. The company maintains leadership under CEO Hui Cheng and has reported steady revenue growth in its feed, pharmaceutical, and food farming segments over recent years. TECON BIOLOGY continues to strengthen its market position through upgrading product offerings and expanding its operational scale in the animal husbandry industry, contributing to its goal of becoming a premier health breeding service provider and safe food supplier in China. The company reported notable financial performance with increased revenue and operating income in 2024–2025, reflecting its robust operational growth despite challenging market conditions. It has made advances in cold chain logistics for meat product distribution and improved its agricultural products division through integration of storage, processing, and import-export services. TECON BIOLOGY remains focused on innovation in vaccine development and animal nutrition to support sustainable livestock production. TECON BIOLOGY Co.LTD is listed on the Shenzhen Stock Exchange under ticker 002100.SZ. The company remains a major player in China's veterinary biological products market and continues to develop its comprehensive animal health and breeding service offerings aligned with modern agricultural industry needs.